Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers
Open Access
Abstract
Breast cancer stem cells (CSCs) are resistant to most cancer therapeutics and contribute to tumor recurrence and metastasis. Two breast CSC-promoting transcription factors, truncated glioma-associated oncogene homolog 1 (tGLI1) and signal transducer and activator of transcription 3 (STAT3), have been reported to be frequently co-expressed in HER2-enriched breast cancer and triple-negative breast cancer (TNBC), undergo protein-protein interactions for gene regulation and activation, and functionally cooperate to promote breast CSCs. STAT3 can be activated by activated interleukin-6 receptor/glycoprotein-130 (IL-6R/GP130). Co-targeting of tGLI1 and IL-6R/GP130 has not been investigated in breast cancer or any tumor type. Here, we report that tGLI1 and GP130 are co-overexpressed in the majority of HER2-enriched breast cancers and TNBCs at 53.8% and 44.4%, respectively. tGLI1+IL-6/IL-6R/GP130 signaling is frequently co-enriched and co-activated in HER2-enriched breast cancer and TNBC when compared to luminal subtypes. tGLI1+GP130 co-overexpression strongly promotes CSCs of HER2-enriched breast cancer and TNBC. FDA-approved tGLI1 inhibitor Ketoconazole and GP130 inhibitor Bazedoxifene synergize against breast cancer proliferation and CSC phenotypes in vitro and reduce TNBC tumor growth and metastatic burden in vivo. Our study demonstrates, for the first time, that co-targeting tGLI1 and IL-6R/GP130/STAT3 signaling pathways is synergistic against HER2-enriched breast cancer and TNBC, warranting future clinical investigations.Keywords
Funding Information
- U.S. Department of War (W81XWH-17-1-0044, W81XWH-19-1-0072, W81XWH-19-1-0753, W81XWH-20-1-0044, HT9425-24-1-0889, 1R01CA228137-01A1, 1R21CA286225-01A1)
- National Institutes of Health (W81XWH-17-1-0044, W81XWH-19-1-0072, W81XWH-19-1-0753, W81XWH-20-1-0044, HT9425-24-1-0889, 1R01CA228137-01A1, 1R21CA286225-01A1)
This publication has 69 references indexed in Scilit:
- Bazedoxifene – a promising brain active SERM that crosses the blood brain barrier and enhances spatial memoryPsychoneuroendocrinology, 2020
- Role of OCT4 in cancer stem-like cells and chemotherapy resistanceBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancerBreast Cancer Research and Treatment, 2019
- JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and ChemoresistanceCell Metabolism, 2018
- CYP3A4-based drug–drug interaction: CYP3A4 substrates’ pharmacokinetic properties and ketoconazole dose regimen effectEuropean Journal of Drug Metabolism and Pharmacokinetics, 2014
- Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell PopulationMolecular Cell, 2012
- A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate CancerJournal of Urology, 2010
- REDUCTION IN SERUM IL-6 AFTER VACINATION OF BREAST CANCER PATIENTS WITH TUMOUR-ASSOCIATED ANTIGENS IS RELATED TO ESTROGEN RECEPTOR STATUSCytokine, 2000
- Two Signals Are Necessary for Cell Proliferation Induced by a Cytokine Receptor gp130: Involvement of STAT3 in Anti-ApoptosisImmunity, 1996
- A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin‐6.The EMBO Journal, 1995